Non-invasive monitoring and treat-to-target approach are cost-effective in patients with mild-moderate ulcerative colitis.
Fiche publication
Date publication
novembre 2022
Journal
Alimentary pharmacology & therapeutics
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Cortesi PA, Fiorino G, Peyrin-Biroulet L, Mantovani LG, Jairath V, Paridaens K, Andersson FL, Danese S
Lien Pubmed
Résumé
There are no data to assess the value associated with a treat-to-target (T2T) strategy based on tight control of mild-moderate ulcerative colitis (UC).
Mots clés
calprotectin, cost-effectiveness, mild-moderate ulcerative colitis, monitoring
Référence
Aliment Pharmacol Ther. 2022 11 15;: